<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36973">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02625207</url>
  </required_header>
  <id_info>
    <org_study_id>A4001110</org_study_id>
    <nct_id>NCT02625207</nct_id>
  </id_info>
  <brief_title>THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC</brief_title>
  <official_title>A Phase 1, Open-label, Parallel-group Study To Assess The Effect Of Cyp3a5 Genotype On The Pharmacokinetics Of Maraviroc And Cyp3a5-derived Metabolites With And Without Darunavir/Cobicistat In African-american And Caucasian Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be an open-label, parallel group, multiple dose study in approximately 48 healthy
      male or female subjects of African American and Caucasian self-reported race, to assess the
      effect of CYP3A5 genotype on the PK of MVC and CYP3A5-derived metabolites. Maraviroc and
      CYP3A5-derived metabolite PK will also be compared between African-Americans and Caucasians
      in subjects carrying two copies of the dysfunctional CYP3A5 alleles (*3, *6, and/or *7).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be an open-label, parallel group, multiple dose study in approximately 48 healthy
      male or female subjects of African American and Caucasian self-reported race, to assess the
      effect of CYP3A5 genotype on the PK of MVC and CYP3A5-derived metabolites. Maraviroc and
      CYP3A5-derived metabolite PK will also be compared between African-Americans and Caucasians
      in subjects carrying two copies of the dysfunctional CYP3A5 alleles (*3, *6, and/or *7).

      Dysfunctional genetic variants for CYP3A5, CYP3A4 and SLCO1B1 will be genotyped for subjects
      who participate in the pre-screening. Subjects who meet the inclusion/exclusion criteria for
      study participation will be placed into the study cohorts based on race and the number of
      functional (*1) and dysfunctional CYP3A5 alleles (*3, *6, and *7) CYP3A5 alleles.

      Cohort 1 (n=12; African-American): No CYP3A5*1 alleles (poor metabolizer). Cohort 2 (n=12;
      African-American): One CYP3A5*1 allele (intermediate metabolizer).

      Cohort 3 (n=12; African-American): Two CYP3A5*1 alleles (extensive metabolizer).

      Cohort 4 (n=12; Caucasian): No CYP3A5*1 alleles (poor metabolizer).

      Study Treatments:

      Part 1 Days 1-5: Maraviroc 300 mg BID in fasted state (AM dose only on Day 5). Part 2
      (Cohorts 1 and 3 only) Days 1-10: Maraviroc 150 mg QD plus darunavir/cobicistat 800/150 mg
      QD with food.

      Pharmacokinetics of MVC, PF-6857639, PF-6857640 and other hydroxylated metabolites with
      formation mediated by CYP3A5 (if present) will be assessed on Part 1, Day 5 and Part 2, Days
      10-11. Blood samples will be collected for a full PK profile.

      Subjects will be confined to the Clinical Research Unit (CRU) the day prior to dosing on Day
      1 (Day 0) and discharged on Part 1, Day 6 and on Part 2, Day 11 (Cohorts 1 and 3 only).
      Subjects enrolled into Cohorts 1 and 3 may be confined to the CRU without the need to be
      discharged between Part 1 and Part 2.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maraviroc AUC</measure>
    <time_frame>15 days</time_frame>
    <description>Maraviroc area under the time plasma concentration time curve (AUC): AUC12 (Part 1), AUC24 (Part 2) and AUCparent/metabolite ratios</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maraviroc and metabolite Cavg</measure>
    <time_frame>15 days</time_frame>
    <description>Maraviroc, PF-6857639, PF-6857640 and other hydroxylated metabolite with formation mediated by CYP3A5 (if present) average plasma concentration (Cavg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maraviroc and metabolite Cmax</measure>
    <time_frame>15 days</time_frame>
    <description>Maraviroc, PF-6857639, PF-6857640 and other hydroxylated metabolite with formation mediated by CYP3A5 (if present) peak plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maraviroc and metabolite Tmax</measure>
    <time_frame>15 days</time_frame>
    <description>Maraviroc, PF-6857639, PF-6857640 and other hydroxylated metabolite with formation mediated by CYP3A5 (if present)time to Cmax (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maraviroc and metabolite C12h</measure>
    <time_frame>15 days</time_frame>
    <description>Maraviroc, PF-6857639, PF-6857640 and other hydroxylated metabolite with formation mediated by CYP3A5 (if present) plasma concentration at 12 hours (C12h; Part 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maraviroc and metabolite C24h</measure>
    <time_frame>15 days</time_frame>
    <description>Maraviroc, PF-6857639, PF-6857640 and other hydroxylated metabolite with formation mediated by CYP3A5 (if present) plasma concentration at 24 hours (C24h; Part 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maraviroc metabolite AUC</measure>
    <time_frame>15 days</time_frame>
    <description>PF-6857639, PF-6857640 and other hydroxylated metabolite with formation mediated by CYP3A5 (if present) area under the time plasma concentration time curve (AUC): AUC12 (Part 1), AUC24 (Part 2) and AUCparent/metabolite ratios</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)</measure>
    <time_frame>15 days</time_frame>
    <description>Safety and tolerability assessed by reported adverse events, vital signs, 12-lead electrocardiogram (ECG) and laboratory safety assessments</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>African-Americans with No CYP3A5*1 alleles (poor metabolizer)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>African-Americans with One CYP3A5*1 allele (intermediate metabolizer)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>African-Americans with Two CYP3A5*1 alleles (extensive metabolizer)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Caucasians with No CYP3A5*1 alleles (poor metabolizer)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc (Part 1)</intervention_name>
    <description>300 mg twice daily x 5 days</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <other_name>Selzentry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc (Part 2)</intervention_name>
    <description>150 mg once daily x 10 days</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>Selzentry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir/cobicistat (Part 2)</intervention_name>
    <description>800/150 mg once daily x 10 days</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>Prezcobix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs)

          -  Healthy female subjects and/or male subjects of African-American/Black or Caucasian
             race

        Exclusion Criteria:

          -  History of regular alcohol consumption exceeding 7 drinks/week for females or 14
             drinks/week for males

          -  Treatment with an investigational drug within 30 days

          -  Screening supine blood pressure &lt;90 or &gt;/=140 mm Hg (systolic) or &lt;60 or &gt;/= 90 mm Hg
             (diastolic), following at least 5 minutes of supine rest

          -  Use of prescription or nonprescription drugs and dietary supplements within 7 days or
             5 half-lives (whichever is longer) prior to the first dose of study medication.

          -  Use of tobacco- or nicotine-containing products in excess of the equivalent of 5
             cigarettes per day

          -  Subjects who have a CYP3A4*22 allele and/or have a SLCO1B1 *5 or *15 allele
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer New Haven Clinical Research Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4001110&amp;StudyName=A%20Phase%201%2C%20Open-label%2C%20Parallel-group%20Study%20To%20Assess%20The%20Effect%20Of%20Cyp3a5%20Genotype%20On%20The%20Pharmacokinetics%20Of%20Maraviroc%20And%20Cyp3a5-derived%20Metabolites%20With%20And%20Without%20Darunavir%2Fcobicistat%20In%20African-american%20And%20Caucasian%20Healthy%20Volunteers</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 11, 2016</lastchanged_date>
  <firstreceived_date>October 20, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Maraviroc, CYP3A5, pharmacokinetics, pharmacogenomics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cobicistat</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
